Meagan Wasfy

Dr. Meagan Wasfy


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 May 2021 in Current Treatment Options in Cardiovascular Medicine
Verified
Journal Article
Closed access
PDF file
BPBradley J. Petek
Bradley J. Petek
SGSarah K. Gustus
Sarah K. Gustus
MWMeagan Wasfy
Meagan Wasfy

28 August 2023 in JACC
Verified
Journal Article
Closed access
BPBradley J. Petek
Bradley J. Petek
ECEugene H. Chung
Eugene H. Chung
JKJonathan H. Kim
Jonathan H. Kim
RLRachel Lampert
Rachel Lampert
BLBenjamin D. Levine
Benjamin D. Levine
MWMeagan Wasfy
Meagan Wasfy

18 May 2022 in British Journal of Sports Medicine
Verified
Journal Article
Closed access
PDF file
NMNathaniel Moulson
Nathaniel Moulson
SGSarah K Gustus
Sarah K Gustus
CSChristina Scirica
Christina Scirica
BPBradley J Petek
Bradley J Petek
CVCaroyln Vanatta
Caroyln Vanatta
MWMeagan Wasfy
Meagan Wasfy
Objectives: Persistent or late-onset cardiopulmonary symptoms following COVID-19 may occur in athletes despite a benign initial course. We examined the yield of cardiac evaluation, including cardiopulmonary exercise testing (CPET), in athletes with cardiopulmonary symptoms after COVID-19, compared CPETs in these athletes and those without COVID-19 and evaluated longitudinal changes in CPET with improvement in symptoms.Methods: This prospective cohort study evaluated young (18–35 years old) athletes referred for cardiopulmonary symptoms that were present>28 days from COVID-19 diagnosis. CPET findings in post-COVID athletes were compared with a matched reference group of healthy athletes without COVID-19. Post-COVID athletes underwent repeat CPET between 3 and 6 months after initial evaluation.Results: Twenty-one consecutive post-COVID athletes with cardiopulmonary symptoms (21.9±3.9 years old, 43% female) were evaluated 3.0±2.1 months after diagnosis. No athlete had active inflammatory heart disease. CPET reproduced presenting symptoms in 86%. Compared with reference athletes (n=42), there was similar peak VO2but a higher prevalence of abnormal spirometry (42%) and low breathing reserve (42%). Thirteen athletes (62%) completed longitudinal follow-up (4.8±1.9 months). The majority (69%) had reduction in cardiopulmonary symptoms, accompanied by improvement in peak VO2and oxygen pulse, and reduction in resting and peak heart rate (all p<0.05).Conclusion: Despite a high burden of cardiopulmonary symptoms after COVID-19, no athlete had active inflammatory heart disease. CPET was clinically useful to reproduce symptoms with either normal testing or identification of abnormal spirometry as a potential therapeutic target. Improvement in post-COVID symptoms was accompanied by improvements in CPET parameters.

7 December 2022 in British Journal of Sports Medicine
Verified
Journal Article
Open access
PDF file
RGRachel Grashow
Rachel Grashow
TSTaylor Valencia Shaffer-Pancyzk
Taylor Valencia Shaffer-Pancyzk
IDInana Dairi
Inana Dairi
HLHang Lee
Hang Lee
DMDean Marengi
Dean Marengi
ABAaron Baggish
Aaron Baggish
Objective To examine the relationships between age, healthspan and chronic illness among former professional American-style football (ASF) players. Methods We compared age-specific race-standardised and body mass index-standardised prevalence ratios of arthritis, dementia/Alzheimer’s disease, hypertension and diabetes among early adult and middle-aged (range 25–59 years) male former professional ASF players (n=2864) with a comparator cohort from the National Health and Nutrition Examination Survey and National Health Interview Survey, two representative samples of the US general population. Age was stratified into 25–29, 30–39, 40–49 and 50–59 years. Results Arthritis and dementia/Alzheimer’s disease were more prevalent among ASF players across all study age ranges (all p<0.001). In contrast, hypertension and diabetes were more prevalent among ASF players in the youngest age stratum only (p<0.001 and p<0.01, respectively). ASF players were less likely to demonstrate intact healthspan (ie, absence of chronic disease) than the general population across all age ranges. Conclusion These data suggest the emergence of a maladaptive early ageing phenotype among former professional ASF players characterised by premature burden of chronic disease and reduced healthspan. Additional study is needed to investigate these findings and their impact on morbidity and mortality in former ASF players and other athlete groups.

2 November 2022 in European Journal of Preventive Cardiology
Verified
Journal Article
Closed access
PDF file
BPBradley J Petek
Bradley J Petek
TCTimothy W Churchill
Timothy W Churchill
SGSarah K Gustus
Sarah K Gustus
MSMark W Schoenike
Mark W Schoenike
MNMatthew Nayor
Matthew Nayor
MWMeagan Wasfy
Meagan Wasfy
Ventilatory efficiency (⁠ V˙E/ V˙CO2) during exercise is defined as the ratio of minute ventilation (⁠ V˙E) and carbon dioxide output (⁠ V˙CO2) and reflects matching of alveolar ventilation and pulmonary perfusion as well as ventilatory drive.1 Abnormally high V˙E/ V˙CO2 is important diagnostically and prognostically in the setting of cardiopulmonary disease.1 Current clinical guidelines propose a total slope (⁠ V˙E/ V˙CO2-total) < 30 as normal,1 with higher cutoffs (⁠ V˙E/ V˙CO2-total < 34) providing prognostic value in specific diseases.2,3 While some recommend measurement of V˙E/ V˙CO2-total slope over only the linear portion of the curve from the start of exercise to the second ventilatory threshold (VT2, also known as the respiratory compensation point),4,5 V˙E/ V˙CO2-total is often measured over the entirety of the exercise effort given robust prognostic data in heart failure using this technique.2,3,6 Normative values for V˙E/ V˙CO2 have been derived from general population cohorts,4,6 but remain limited in athletes.7,8 By virtue of high motivation and cardiorespiratory fitness, athletes are capable of sustaining a graded exercise effort well beyond the VT2 after which V˙E increases relative to V˙CO2 in late exercise even in the absence of cardiopulmonary disease. Resultant elevation in V˙E/ V˙CO2-total when measured through the end of exercise may confound assessment for pathology. The primary aims of this study were to define athlete-specific normative values for V˙E/ V˙CO2 and to assess the performance of existing cutoffs and predictive equations for V˙E/ V˙CO2 in athletes. This prospective cohort study included a select group of athletes who underwent effort-limited clinically indicated cardiopulmonary exercise testing (CPET) on either the treadmill or upright cycle ergometer from 2011 to 2021 in the Massachusetts General Hospital Cardiovascular Performance Program. As previously described, rigorous exclusion criteria were used to generate a cohort free from clinically evident cardiopulmonary disease.9 Endurance sports were defined as distance running, cycling, rowing, triathlon, and/or swimming. V˙E/ V˙CO2-total was defined as the V˙E vs. V˙CO2 slope from the ramp start to peak exercise, V˙E/ V˙CO2-start-VT1 as the slope from the ramp start to the first ventilatory threshold (VT1), and V˙E/ V˙CO2-Nadir as the lowest continuous 30 s average V˙E/ V˙CO2 ratio during exercise. Peak V˙O2 (p V˙O2) was defined as the highest oxygen uptake, averaged over 30 s, during the last minute of exercise. Gas exchange data were analysed using a mid-5-of-7 averaging algorithm (i.e. the moving average of five breaths excluding the lowest and highest). Categorical variables are presented as n (%) and continuous variables are presented as mean [standard deviation (SD)]. Linear regression was used to assess the relationship between V˙E/ V˙CO2 and other variables. The performance of existing V˙E/ V˙CO2 prediction equations was assessed by regressing measured on predicted V˙E/ V˙CO2 and by Bland–Altman analysis. The upper limit of normal (ULN) was defined as >90th percentile for predicted V˙E/ V˙CO2-total,6 and predicted V˙E/ V˙CO2-Nadir +(1.66 × SD).4 Statistical analyses were performed using R (R Core Team, Vienna, Austria, 2022). This study was approved by the Massachusetts General Brigham Institutional Review Board. In 521 athletes (age = 38 ± 15 years, 33% female, 91% white), exercise was completed on the treadmill in 292 (56%) and cycle ergometer in 229 (44%). Most participants were endurance athletes (n = 330, 63%), with the remaining participating in mixed/other sports (n = 191, 37%). Table 1 presents V˙E/ V˙CO2 and p V˙O2stratified by age and sex. V˙E/ V˙CO2-total exceeded the guideline-recommended cutoff of 30 in 66/172 (38%) females and 106/349 (30%) males and exceeded the prognostic threshold of 34 in 30/172 (17%) females and 40/349 (11%) males. In the total population, V˙E/ V˙CO2 exceeded the prognostic threshold of 34 in 70/521 (13%) athletes using V˙E/ V˙CO2-total, 10/521 (1.9%) using V˙E/ V˙CO2-start-VT1, and 2/521 (0.4%) using V˙E/ V˙CO2-Nadir. Of the 70 athletes with V˙E/ V˙CO2-total >34, only 8/70 (11.4%) had V˙E/ V˙CO2-start-VT1 > 34 and 2/70 (2.9%) had V˙E/ V˙CO2-Nadir >34 (Figure 1).

12 November 2021 in Physiological Reports
Verified
Journal Article
Open access
PDF file
BPBradley J. Petek
Bradley J. Petek
TCTimothy W. Churchill
Timothy W. Churchill
JGJ. Sawalla Guseh
J. Sawalla Guseh
GLGarrett Loomer
Garrett Loomer
SGSarah K. Gustus
Sarah K. Gustus
MWMeagan Wasfy
Meagan Wasfy
Cardiopulmonary exercise testing (CPET) guidelines recommend analysis of the oxygen (O2) pulse for a late exercise plateau in evaluation for obstructive coronary artery disease (OCAD). The diagnostic...